Nevro (NVRO) Hits New 52-Week High: What's Driving the Stock?
Shares of Nevro Corp. NVRO scaled a new 52-week high of $117.51 on Dec 24, closing the session marginally lower at $116.65. In fact, the stock has rallied 36.8% since its third-quarter earnings announcement on Nov 6.
Higher demand for implants, solid U.S. patient trial growth and raised guidance for 2019 prompted the rally.
Let us take a closer look at the factors driving growth.
Robust Q3 Earnings
The company exited the third quarter on a promising note, with narrower loss and higher revenues than the Zacks Consensus Estimate.
In the quarter under review, international revenues were up 5% at constant currency.
U.S. revenues for the quarter also registered a 5% year-over-year uptick. U.S. patient trials and permanent implants each witnessed 18% growth on a year-over-year basis.
Gross profit in the quarter rose 4% year over year.
The lifted revenue outlook for 2019 buoys optimism among investors, indicating the continuation of this bullish trend through the rest of the year.
Other Encouraging Factors
In November 2019, Nevro commercially launched the Senza Omnia Spinal Cord Stimulation System on the heels of attaining the FDA approval for the same. Investors have been optimistic about the company’s growth prospects since the crucial development.
Meanwhile, Nevro has been witnessing a great run on the bourses in the past year. The stock has surged 211.2%, higher than the broader industry’s growth of 22.5%. The company currently has a market cap of $3.62 billion.
Zacks Rank & Stocks to Consider
Nevro currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space are Haemonetics Corporation HAE, NuVasive, Inc NUVA and Omnicell (OMCL), each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Haemonetics has a projected long-term earnings growth rate of 13.5%.
NuVasive has an expected long-term earnings growth rate of 10.9%.
Omnicell has a long-term earnings growth rate of 12.5%.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Omnicom Group Inc. (OMC) : Free Stock Analysis Report
Nevro Corp. (NVRO) : Free Stock Analysis Report
Haemonetics Corporation (HAE) : Free Stock Analysis Report
NuVasive, Inc. (NUVA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
